- Home
- SFNC vs RARE Comparison
SFNC vs RARE Comparison
Compare SFNC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SFNC | RARE |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SFNC | RARE |
|---|---|---|
| Price | $19.59 | $36.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $22.75 | ★ $85.20 |
| AVG Volume (30 Days) | 989.9K | ★ 1.4M |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $630,598,000.00 |
| Revenue This Year | $27.12 | $19.09 |
| Revenue Next Year | $7.58 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $17.00 | $25.81 |
| 52 Week High | $24.29 | $49.19 |
Technical Indicators
Market Signals| Indicator | SFNC | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 67.67 | 61.44 |
| Support Level | $18.41 | $35.65 |
| Resistance Level | $19.94 | $36.74 |
| Average True Range (ATR) | 0.40 | 1.43 |
| MACD | 0.15 | 0.18 |
| Stochastic Oscillator | 84.34 | 53.64 |
Price Performance
Historical ComparisonAbout SFNC Simmons First National Corporation
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.